866-997-4948(US-Canada Toll Free)

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Oncology

No. of Pages : 190 Pages


Global Markets Directs, \'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia).
  • A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) 10
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics under Development by Companies 12
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Products under Development by Companies 22
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics Development 26
Bristol-Myers Squibb Company 26
Athersys, Inc. 27
Daiichi Sankyo Company, Ltd 28
Gamida Cell Ltd. 29
Nanotherapeutics, Inc. 30
Bio-Path Holdings, Inc. 31
Novartis AG 32
Nippon Shinyaku Co., Ltd. 33
Pfizer Inc. 34
Sun Pharmaceutical Industries Limited 35
Aduro BioTech 36
Celgene Corporation 37
Incyte Corporation 38
Ariad Pharmaceuticals, Inc. 39
Choongwae Pharma Corp 40
Ilyang Pharmaceutical Co., Ltd 41
Jiangsu Hengrui Medicine Co., Ltd. 42
Synta Pharmaceuticals Corp. 43
Natco Pharma Limited 44
SymBio Pharmaceuticals Limited 45
Cancer Research Technology Limited 46
Nerviano Medical Sciences S.r.l. 47
Deciphera Pharmaceuticals, LLC 48
Stemline Therapeutics, Inc. 49
Onconova Therapeutics, Inc 50
KaloBios Pharmaceuticals, Inc. 51
Kinex Pharmaceuticals, LLC 52
EpiZyme, Inc. 53
Targa Therapeutics Corp. 54
EirGen Pharma Ltd. 55
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 62
StemEx - Drug Profile 62
ponatinib - Drug Profile 64
ponatinib - Drug Profile 66
MultiStem - Drug Profile 68
azacitidine - Drug Profile 71
BMS-833923 - Drug Profile 73
bafetinib - Drug Profile 75
SL-501 - Drug Profile 77
ON-044580 - Drug Profile 78
SyB-0702 - Drug Profile 79
KB-004 - Drug Profile 80
HuM-195/rGel - Drug Profile 82
ciclopirox olamine - Drug Profile 83
Triapine - Drug Profile 84
exatecan mesylate - Drug Profile 86
Bcr-abl Multipeptide Vaccine - Drug Profile 88
erismodegib - Drug Profile 89
BP-100-1.01 - Drug Profile 91
danusertib - Drug Profile 93
rebastinib - Drug Profile 95
NRC-AN-019 - Drug Profile 97
HM-95091 - Drug Profile 99
KX-01 - Drug Profile 100
TALL-104 - Drug Profile 102
GVAX CML Vaccine - Drug Profile 104
MRx-102 - Drug Profile 105
CWP-232291 - Drug Profile 107
Interleukin-1 Receptor Associated Protein Targeting Antibody - Drug Profile 109
ORB-0001 - Drug Profile 110
radotinib - Drug Profile 111
D-12-PGJ-3 - Drug Profile 113
HHGV-678 - Drug Profile 114
Lenaldekar - Drug Profile 115
Sun-K706 - Drug Profile 116
KPT-330 - Drug Profile 117
EPZ-5676 - Drug Profile 119
OP-449 Backup - Drug Profile 120
ADAR1 Inhibitors - Drug Profile 121
OP-449 - Drug Profile 122
interferon alfa-2b biosimilar - Drug Profile 124
DP-00605 - Drug Profile 125
D-824 - Drug Profile 126
Drugs Targeting ABL - Drug Profile 127
ON-012380 - Drug Profile 128
ON-044590 - Drug Profile 129
WT1 DNA Vaccine - Drug Profile 130
TR-120 - Drug Profile 131
NOV-120501 - Drug Profile 132
Drug For Chronic Myeloid Leukemia - Drug Profile 133
Protein Arginine Methyltransferase 5 Inhibitors - Drug Profile 134
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Drug Profile Updates 135
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Discontinued Products 172
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Dormant Products 174
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 176
Featured News & Press Releases 176

Appendix 186
Methodology 186
Coverage 186
Secondary Research 186
Primary Research 186
Expert Panel Validation 186
Contact Us 187
Disclaimer 187

List of Table


Number of Products Under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2013 13
Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H2 2013 14
Number of Products under Development by Companies, H2 2013 16
Number of Products under Development by Companies, H2 2013 (Contd..1) 17
Number of Products under Development by Companies, H2 2013 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2013 20
Comparative Analysis by Late Stage Development, H2 2013 21
Comparative Analysis by Mid Clinical Stage Development, H2 2013 22
Comparative Analysis by Early Clinical Stage Development, H2 2013 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 24
Products under Development by Companies, H2 2013 25
Products under Development by Companies, H2 2013 (Contd..1) 26
Products under Development by Companies, H2 2013 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2013 28
Bristol-Myers Squibb Company, H2 2013 29
Athersys, Inc., H2 2013 30
Daiichi Sankyo Company, Ltd, H2 2013 31
Gamida Cell Ltd., H2 2013 32
Nanotherapeutics, Inc., H2 2013 33
Bio-Path Holdings, Inc., H2 2013 34
Novartis AG, H2 2013 35
Nippon Shinyaku Co., Ltd., H2 2013 36
Pfizer Inc., H2 2013 37
Sun Pharmaceutical Industries Limited, H2 2013 38
Aduro BioTech, H2 2013 39
Celgene Corporation, H2 2013 40
Incyte Corporation, H2 2013 41
Ariad Pharmaceuticals, Inc., H2 2013 42
Choongwae Pharma Corp, H2 2013 43
Ilyang Pharmaceutical Co., Ltd, H2 2013 44
Jiangsu Hengrui Medicine Co., Ltd., H2 2013 45
Synta Pharmaceuticals Corp., H2 2013 46
Natco Pharma Limited, H2 2013 47
SymBio Pharmaceuticals Limited, H2 2013 48
Cancer Research Technology Limited, H2 2013 49
Nerviano Medical Sciences S.r.l., H2 2013 50
Deciphera Pharmaceuticals, LLC, H2 2013 51
Stemline Therapeutics, Inc., H2 2013 52
Onconova Therapeutics, Inc, H2 2013 53
KaloBios Pharmaceuticals, Inc., H2 2013 54
Kinex Pharmaceuticals, LLC, H2 2013 55
EpiZyme, Inc., H2 2013 56
Targa Therapeutics Corp., H2 2013 57
EirGen Pharma Ltd., H2 2013 58
Assessment by Monotherapy Products, H2 2013 59
Assessment by Stage and Route of Administration, H2 2013 61
Assessment by Stage and Molecule Type, H2 2013 64
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Drug Profile Updates 138
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Discontinued Products 175
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Discontinued Products (Contd..1) 176
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Dormant Products 177
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Dormant Products (Contd..1) 178

List of Chart


Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2013 13
Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 19
Late Stage Products, H2 2013 21
Mid Clinical Stage Products, H2 2013 22
Early Clinical Stage Products, H2 2013 23
Discovery and Pre-Clinical Stage Products, H2 2013 24
Assessment by Monotherapy Products, H2 2013 59
Assessment by Route of Administration, H2 2013 60
Assessment by Stage and Route of Administration, H2 2013 61
Assessment by Molecule Type, H2 2013 62
Assessment by Stage and Molecule Type, H2 2013 63

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *